Light Mode
$32.86 ↑ +0.00 (+0.00%) Trading Up from the previous close of $32.86, $0.61 below the day’s high of $33.47
+9.86 (+42.87%) / 6M
Momentum, market sentiment, and recent alerts
SGP reads very good: the 12-month move is +24.5%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. Its lead product candidate, Bimatoprost Drug Pad-IOL System (BIM-IOL System), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) for patients who have wither open-angel glaucoma (OAG) or ocular hypertension (OHT). The company was founded in January 2019 by Malik Y. Kahook and Glenn Sussman and is headquartered in Aliso Viejo, CA.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.